Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
[More]
Researchers at Johns Hopkins report that hospitalized patients do not receive more than one in 10 doses of doctor-ordered blood thinners prescribed to prevent potentially lethal or disabling blood clots, a decision they say may be fueled by misguided concern by patients and their caregivers.
[More]
The Society of Interventional Radiology announces the release of "Updates in Interventional Radiology 2013," a concise reference of the current literature most relevant to the specialty.
[More]
The temporary placement of umbrella-like, metal mesh filters in abdominal veins to stop potentially lethal blood clots from traveling to the lungs during and after weight loss surgery may actually increase the risk of death in morbidly obese patients, according to new Johns Hopkins research.
[More]
Physicians at Monash University and The Alfred Hospital in Melbourne, Australia describe the logistic, medical, and societal challenges faced in treating spine trauma in morbidly obese patients.
[More]
Touted for safety, ease and patient convenience, peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications.
[More]
Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.
[More]
A major challenge facing today's health care community is to find ways to lower costs without compromising clinical quality. Taking that challenge to task, researchers at Medstar Health and Georgetown University School of Medicine, Washington DC, report success in using a concept called "value-based analysis," which simultaneously measures quality and cost and addresses inefficiencies in care.
[More]
Women who have suffered a still birth or have medical conditions including varicose veins, inflammatory bowel disease (IBD) or heart disease are at greater risk of developing dangerous blood clots after giving birth, a study has revealed.
[More]
Newly identified pregnancy-related events, such as stillbirth or pre-term birth, may dramatically increase a woman's risk of developing a potentially deadly blood clot immediately after pregnancy, according to the results of a large, population-based study published online today in Blood, the Journal of the American Society of Hematology.
[More]
An evaluation of practice patterns in California hospitals showed a large variation in the use of metal devices called inferior vena cava filters, or VCFs, despite little evidence of their safety and effectiveness.
[More]
New research from the UC Davis Comprehensive Cancer Center, published in the Journal of Surgical Research, may help clinicians determine which patients are at highest risk for post-surgical blood clots in the legs or lungs.
[More]
The frequency of vena cava filter use to prevent migration of blood clots to the lungs in patients with acute venous thromboembolism appears to vary widely and be associated with which hospital provides the patient care, according to a study of California hospitals published Online First by JAMA Internal Medicine, a JAMA Network publication.
[More]
Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction.
[More]
New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).
[More]
Findings from two Danish studies have shown that ABO blood type, both alone and in combination with the presence of factor V and prothrombin mutations, is associated with increases in risk for venous thromboembolism.
[More]
The benefits of extended prophylactic anticoagulation with rivaroxaban in acutely ill hospital patients are outweighed by an increased bleeding risk, shows a study in The New England Journal of Medicine.
[More]
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
[More]
The non-O ABO blood type is the most important risk factor for venous thromboembolism (blood clots in veins), making up 20% of attributable risk for the condition, according to a new study in CMAJ (Canadian Medical Association Journal).
[More]
Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.
[More]